THERAPY DOSSIER · th-9e2c37bfc5fd

Valganciclovir-induced microglial depletion in CD11b-thymidine kinase mice

Drug

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: 2001
Development stage: Not recorded
ChEMBL record: CHEMBL1200454 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Valganciclovir hydrochloride; Valcyte; RO-107-9070/194; RS-79070-194
Note: Not recorded

Clinical trials 8

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06034925 ↗PHASE4completed

Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

Transplant Complication · CMV

Enrolment: 70 · Results not recorded

NCT00034385 ↗PHASE4completed

Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients

Kidney Transplant

Enrolment: 12 · Results not recorded

NCT05708508 ↗PHASE3recruiting

Immune-guided Cytomegalovirus Preventive Strategy Compared to Universal Prophylaxis in Renal Transplant Patients (ROVALCYTE)

Kidney Transplant Infection

Enrolment: 144 · Results not recorded

NCT06334497 ↗PHASE3recruiting

Letermovir/Valganciclovir Combination Versus Valganciclovir Monotherapy for Treatment of CMV Infections in Kidney Transplant Recipients

Cytomegalovirus Infection

Enrolment: 80 · Results not recorded

NCT02005822 ↗PHASE3completed

Leiden CONCERT Study 2.0 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment (valganciclovir)

Congenital Cytomegalovirus Infection · Sensorineural Hearing Loss

Enrolment: 37 · Results not recorded

NCT00090766 ↗PHASE2/PHASE3completed

Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients

Cytomegalovirus Infections

Enrolment: 63 · Results not recorded

NCT04439916 ↗Phase not recordedrecruiting

Breakthrough CMV DNAemia in Lung Transplantation During Antiviral Prophylaxis With Valganciclovir

Cytomegalovirus Infections

Enrolment: 40 · Results not recorded

NCT00198224 ↗NAcompleted

In Vitro Immunosuppressive Effects of Mycophenolate Mofetil and Valganciclovir in Kidney Transplant Recipients

Renal Failure

Enrolment: 50 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24797413 ↗2014No effect reported

Acute reduction of microglia does not alter axonal injury in a mouse model of repetitive concussive traumatic brain injury.

MouseTBIClosed-head / concussionCD11b-TK transgenic on C57BL/6 background1 mg/mL (low), 10 mg/mL (intermediate) and 50 mg/mL (high)…Administered after repetitive injury

Model: Repetitive closed-skull concussive traumatic brain injury

Reducing the microglial population by 35 to 56 percent did not change the extent of axonal injury at acute or subacute time points, and longer or higher-dose valganciclovir was toxic in this model.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…